Emerging Approaches to the Treatment of Newly Diagnosed Multiple Myeloma
Release Date: October 31, 2018
Expiration Date: October 31, 2019
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
With novel first-line treatments and drug combinations continuing to penetrate the therapeutic landscape in multiple myeloma, it is imperative that community oncologists stay informed and up-to-date on emerging strategies for treating newly diagnosed multiple myeloma (NDMM). In this activity, Dr. Keith Stewart discusses several new treatments for NDMM and compares efficacy and safety data associated with these emerging drugs. He also outlines strategies to ensure that NDMM patients receive the most appropriate agents based on their unique characteristics.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Compare and contrast emerging drug classes for the treatment of newly diagnosed multiple myeloma
- Identify the efficacy and safety of new and emerging agents for the first-line treatment of multiple myeloma
- Outline evidence-based recommendations for the proper sequencing of therapies in patients with newly diagnosed multiple myeloma
Emerging Approaches to the Treatment of Newly Diagnosed Multiple Myeloma – Keith Stewart, MB, ChB, MBA
Instructions for Participation and Credit
This activity is eligible for credit through October 31, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Keith Stewart, MB, ChB, MBA
Professor of Cancer Research
Director, Center for Individualized Medicine
Dr. Keith Stewart is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic. In addition, he serves as the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine, and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart’s current responsibilities at Mayo Clinic relate to the application of genomics to human health across the spectrum of discovery, translation, and application to clinical practice. He has served in several leadership roles across both research and clinical practice at Mayo Clinic, including as Dean for Research in Arizona, and as a member of the Arizona Executive Operations Team and Clinical Practice Committees.
Dr. Stewart has served on multiple boards for both non-profit and commercial organizations, most recently as a non-executive board member with Genomics England, Oncospire Inc. and OneOme Inc. He has more than 25 years of sustained national funding for a laboratory research program. He has authored more than 300 journal articles and other written publications, and has served as an associate editor of Blood and ASH Clinical News. Dr. Stewart’s research interest is in the genomics and biology of myeloma and he has led numerous clinical trials of new drugs for this blood cancer.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-036-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Keith Stewart has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Seattle Genetics, Inc., and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.